Ocular adverse events associated with GLP-1 receptor agonists: a real-world study based on the FAERS database and network pharmacology.

IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Zhan-Yang Luo, Xiang Li, Cui-Ting Chen, Hong-Hua Kang, Zhi-Jie Zhang, Dong Wang, Jing-Ru Gong
{"title":"Ocular adverse events associated with GLP-1 receptor agonists: a real-world study based on the FAERS database and network pharmacology.","authors":"Zhan-Yang Luo, Xiang Li, Cui-Ting Chen, Hong-Hua Kang, Zhi-Jie Zhang, Dong Wang, Jing-Ru Gong","doi":"10.1080/14740338.2024.2419989","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study evaluates the risk of ocular adverse events (AEs) associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) using data from the FDA Adverse Event Reporting System (FAERS) and network pharmacology methods.</p><p><strong>Methods: </strong>FAERS data from 2004 to 2024 were analyzed for ocular AEs linked to GLP-1 RA treatments. Disproportionality analysis (Reporting Odds Ratio, ROR) was used to identify signals, and a drug-gene interaction network explored potential mechanisms.</p><p><strong>Results: </strong>Among 17,785,793 FAERS reports, semaglutide and lixisenatide were significantly associated with ocular AEs, with RORs of 1.25 (95% CI, 1.20-1.31) and 1.96 (95% CI, 1.70-2.27), respectively. Commonly reported AEs included blurred vision, visual impairment, and diabetic retinopathy, with some AEs occurring as early as 10 days after treatment initiation. Gene enrichment analysis highlighted potential links between GLP-1-related genes and ocular AEs.</p><p><strong>Conclusion: </strong>The widespread use of GLP-1 RAs has raised concerns regarding their ophthalmic safety. This study contributes new evidence from real-world data, suggesting that semaglutide and lixisenatide are associated with significant risks of ocular AEs. Further experimental studies are warranted to elucidate the underlying mechanisms and confirm these associations.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14740338.2024.2419989","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This study evaluates the risk of ocular adverse events (AEs) associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) using data from the FDA Adverse Event Reporting System (FAERS) and network pharmacology methods.

Methods: FAERS data from 2004 to 2024 were analyzed for ocular AEs linked to GLP-1 RA treatments. Disproportionality analysis (Reporting Odds Ratio, ROR) was used to identify signals, and a drug-gene interaction network explored potential mechanisms.

Results: Among 17,785,793 FAERS reports, semaglutide and lixisenatide were significantly associated with ocular AEs, with RORs of 1.25 (95% CI, 1.20-1.31) and 1.96 (95% CI, 1.70-2.27), respectively. Commonly reported AEs included blurred vision, visual impairment, and diabetic retinopathy, with some AEs occurring as early as 10 days after treatment initiation. Gene enrichment analysis highlighted potential links between GLP-1-related genes and ocular AEs.

Conclusion: The widespread use of GLP-1 RAs has raised concerns regarding their ophthalmic safety. This study contributes new evidence from real-world data, suggesting that semaglutide and lixisenatide are associated with significant risks of ocular AEs. Further experimental studies are warranted to elucidate the underlying mechanisms and confirm these associations.

与 GLP-1 受体激动剂相关的眼部不良事件:基于 FAERS 数据库和网络药理学的真实世界研究。
研究目的本研究通过分析美国食品药物管理局不良事件报告系统(FAERS)的数据并采用网络药理学方法,评估与胰高血糖素样肽-1受体激动剂(GLP-1 RA)相关的眼部不良事件(AEs)的风险:分析了 2004 年第一季度至 2024 年第一季度的 FAERS 数据,重点关注与 GLP-1 RA 治疗相关的眼部 AE 报告。采用报告几率比(ROR)进行比例失调分析,以确定眼部AEs信号。此外,还利用来自多个公共数据库的数据构建了药物-基因相互作用网络,以阐明这些AEs的潜在机制:结果:对FAERS数据库中的17,785,793份报告进行分析后发现,semaglutide、lixisenatide与眼部AEs之间存在显著关联。塞马鲁肽的ROR为1.25(95% CI,1.20-1.31),利塞那肽的ROR为1.96(95% CI,1.70-2.27),表明眼部AEs风险增加。经常报告的眼部 AE 包括视力模糊、视力损害和糖尿病视网膜病变。发病时间分析表明,有些AE最早可在治疗开始后10天出现。基因富集分析进一步强调了GLP-1相关基因与眼部AEs之间的潜在联系:结论:GLP-1 RAs 的广泛使用引起了人们对其眼科安全性的关注。本研究提供了来自真实世界数据的新证据,表明塞马鲁肽和利塞那肽与眼部AEs的重大风险相关。有必要开展进一步的实验研究,以阐明其潜在机制并确认这些关联。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.90
自引率
3.20%
发文量
97
审稿时长
6-12 weeks
期刊介绍: Expert Opinion on Drug Safety ranks #62 of 216 in the Pharmacology & Pharmacy category in the 2008 ISI Journal Citation Reports. Expert Opinion on Drug Safety (ISSN 1474-0338 [print], 1744-764X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of drug safety and original papers on the clinical implications of drug treatment safety issues, providing expert opinion on the scope for future development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信